Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
21.17
-0.56 (-2.58%)
At close: Apr 16, 2026, 4:00 PM EDT
21.20
+0.03 (0.14%)
After-hours: Apr 16, 2026, 6:24 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 835 employees as of December 31, 2025. The number of employees decreased by 537 or -39.14% compared to the previous year.
Employees
835
Change (1Y)
-537
Growth (1Y)
-39.14%
Revenue / Employee
$2,632,619
Profits / Employee
-$854,383
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 835 | -537 | -39.14% |
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptive Biotechnologies | 624 |
| Agios Pharmaceuticals | 540 |
| Syndax Pharmaceuticals | 298 |
| Zymeworks | 264 |
| Day One Biopharmaceuticals | 178 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
| Definium Therapeutics | 106 |
SRPT News
- 16 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 22 days ago - Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
- 22 days ago - Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 23 days ago - Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 4 weeks ago - Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
- 4 weeks ago - Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - Business Wire
- 4 weeks ago - Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Business Wire
- 6 weeks ago - Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Business Wire